Pyxis Oncology, Inc. Investing Cash Flow
Pyxis Oncology, Inc. (PYXS) reported Investing Cash Flow of $37.67 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivities · last filed 2026-08-13
- Pyxis Oncology, Inc. net cash provided by (used in) investing activities for the quarter ending 2026-06-30 was $21.30M, a 39.19% increase year-over-year.
- Pyxis Oncology, Inc. net cash provided by (used in) investing activities for the quarter ending 2026-03-31 was $16.37M, a 3.46% increase year-over-year.
- Pyxis Oncology, Inc. net cash provided by (used in) investing activities for the quarter ending 2025-12-31 was $16.26M, a 39.00% decline year-over-year.
- Pyxis Oncology, Inc. net cash provided by (used in) investing activities for the quarter ending 2025-09-30 was $11.47M.
- Pyxis Oncology, Inc. net cash provided by (used in) investing activities for fiscal 2025 was $58.86M, a 621.73% increase from fiscal 2024.
- Pyxis Oncology, Inc. net cash provided by (used in) investing activities for fiscal 2024 was $8.15M.
- Pyxis Oncology, Inc. net cash provided by (used in) investing activities for fiscal 2023 was -$104.85M.
- Pyxis Oncology, Inc. net cash provided by (used in) investing activities for fiscal 2022 was -$6.40M.
| Period end | Net Cash Provided by (Used in) Investing Activities 3 month | Net Cash Provided by (Used in) Investing Activities 6 month | Net Cash Provided by (Used in) Investing Activities 9 month | Net Cash Provided by (Used in) Investing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $21.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $37.67M 10-Q · filed 2026-08-13 | $53.93M derived: sum of 3 quarters · filed 2026-08-13 | $65.40M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $16.37M 10-Q · filed 2026-05-14 | $32.63M derived: sum of 2 quarters · filed 2026-05-14 | $44.10M derived: sum of 3 quarters · filed 2026-05-14 | $59.41M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $16.26M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $27.73M derived: sum of 2 quarters · filed 2026-03-23 | $43.04M derived: sum of 3 quarters · filed 2026-08-13 | $58.86M 10-K · filed 2026-03-23 |
| 2025-09-30 | $11.47M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | $26.77M derived: sum of 2 quarters · filed 2026-08-13 | $42.60M 10-Q · filed 2025-11-03 | $69.25M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $15.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $31.13M 10-Q · filed 2026-08-13 | $57.78M derived: sum of 3 quarters · filed 2026-08-13 | $57.77M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $15.82M 10-Q · filed 2026-05-14 | $42.48M derived: sum of 2 quarters · filed 2026-05-14 | $42.47M derived: sum of 3 quarters · filed 2026-05-14 | $42.47M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $26.66M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $26.65M derived: sum of 2 quarters · filed 2026-03-23 | $26.65M derived: sum of 3 quarters · filed 2026-03-23 | $8.15M 10-K · filed 2026-03-23 |
| 2024-09-30 | -$8.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | -$4.00K derived: sum of 2 quarters · filed 2025-11-03 | -$18.50M 10-Q · filed 2025-11-03 | -$8.27M derived: sum of 4 quarters · filed 2025-11-03 |
| 2024-06-30 | $4.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | -$18.49M 10-Q · filed 2025-08-14 | -$8.27M derived: sum of 3 quarters · filed 2025-08-14 | -$1.70M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | -$18.50M 10-Q · filed 2025-05-15 | -$8.27M derived: sum of 2 quarters · filed 2025-05-15 | -$1.70M derived: sum of 3 quarters · filed 2025-05-15 | -$23.95M derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $10.23M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | $16.80M derived: sum of 2 quarters · filed 2025-03-18 | -$5.46M derived: sum of 3 quarters · filed 2025-03-18 | -$104.85M 10-K · filed 2025-03-18 |
| 2023-09-30 | $6.57M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$15.68M derived: sum of 2 quarters · filed 2024-11-12 | -$115.08M 10-Q · filed 2024-11-12 | -$116.94M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | -$22.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | -$121.65M 10-Q · filed 2024-08-14 | -$123.51M derived: sum of 3 quarters · filed 2024-08-14 | -$127.77M derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | -$99.39M 10-Q · filed 2024-05-14 | -$101.25M derived: sum of 2 quarters · filed 2024-05-14 | -$105.52M derived: sum of 3 quarters · filed 2024-05-14 | -$105.65M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | -$1.86M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | -$6.12M derived: sum of 2 quarters · filed 2024-03-21 | -$6.25M derived: sum of 3 quarters · filed 2024-03-21 | -$6.40M 10-K · filed 2024-03-21 |
| 2022-09-30 | -$4.27M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | -$4.39M derived: sum of 2 quarters · filed 2023-11-07 | -$4.54M 10-Q · filed 2023-11-07 | -$4.54M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | -$129.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11 | -$275.00K 10-Q · filed 2023-08-11 | -$275.00K derived: sum of 3 quarters · filed 2023-08-11 | -$275.00K derived: sum of 4 quarters · filed 2023-08-11 |
| 2022-03-31 | -$146.00K 10-Q · filed 2023-05-11 | -$146.00K derived: sum of 2 quarters · filed 2023-05-11 | -$146.00K derived: sum of 3 quarters · filed 2023-05-11 | -$517.00K derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-22 | $0.00 derived: sum of 2 quarters · filed 2023-03-22 | -$371.00K derived: sum of 3 quarters · filed 2023-03-22 | -$590.00K 10-K · filed 2023-03-22 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-01 | -$371.00K derived: sum of 2 quarters · filed 2022-11-01 | -$590.00K 10-Q · filed 2022-11-01 | -$590.00K derived: sum of 4 quarters · filed 2022-11-01 |
| 2021-06-30 | -$371.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | -$590.00K 10-Q · filed 2022-08-15 | -$590.00K derived: sum of 3 quarters · filed 2022-08-15 | |
| 2021-03-31 | -$219.00K 10-Q · filed 2022-05-13 | -$219.00K derived: sum of 2 quarters · filed 2022-05-13 | ||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-29 | -$1.48M 10-K · filed 2022-03-29 | ||
| 2020-09-30 | -$1.48M 10-Q · filed 2021-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |